Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-Blind, Parallel-Group, Single-Dose Trial to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of MSB11022, US-Reference Product, and EU-Reference Medicinal Product (Humira®) in Healthy Subjects

NCT03014947 is registered in ClinicalTrials.gov with Fresenius Kabi SwissBioSim GmbH as lead sponsor.

NCT NCT03014947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03014947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-Blind, Parallel-Group, Single-Dose Trial to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of MSB11022, US-Reference Product, and EU-Reference Medicinal Product (Humira®) in Healthy Subjects
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2014
Completion date
December 31, 2014
Enrollment
237 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects